Ann: Invex Granted Key European Patent for Exenatide, page-72

pretty hard to find a comparative when no one else is focused on IIH apart from IXC. So only company in the market attacking this disease.
I assume with the target audience being 1.6 bill growing 3.4% annually isnt the same market as say cancer but still with no known competitors a successful phase 2 trial, cashed up heading into phase 3, approval from EMA (60% target audience being close to 1 billion) I cant see why this is so out of whack with its current valuation. The only thing holding it back is the uncertainty from the FDA, but as many posters have stated, focus on the EMA and stuff the FDA as majority of the market is there anyway.

I guess one day hopefully the market wakes up and this is trading well above $3. Until then its a waiting game like all stocks, waiting for the right news to gain traction/interest

Thanks for the response, hopefully see you as a holder one day. Cheers